Imatinib Plasma Monitoring-Guided Dose Modification for Managing Imatinib-Related Toxicities in Gastrointestinal Stromal Tumor Patients.
10.3346/jkms.2013.28.8.1248
- Author:
Shinkyo YOON
1
;
Min Hee RYU
;
Changhoon YOO
;
Mo Youl BECK
;
Baek Yeol RYOO
;
Yoon Koo KANG
Author Information
1. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. ykkang@amc.seoul.kr
- Publication Type:Case Reports ; Research Support, Non-U.S. Gov't
- Keywords:
Gastrointestinal Stromal Tumors (GIST);
Imatinib;
Imatinib Plasma Monitoring;
Dose-Modification
- MeSH:
Aged;
Antineoplastic Agents/blood/*therapeutic use;
Benzamides/blood/*therapeutic use;
Drug Monitoring;
Exons;
Gastrointestinal Neoplasms/*drug therapy/pathology/radiography;
Gastrointestinal Stromal Tumors/*drug therapy/pathology/radiography;
Humans;
Liver Neoplasms/secondary;
Male;
Mutation;
Piperazines/blood/*therapeutic use;
Positron-Emission Tomography;
Proto-Oncogene Proteins c-kit/genetics;
Pyrimidines/blood/*therapeutic use;
Tomography, X-Ray Computed
- From:Journal of Korean Medical Science
2013;28(8):1248-1252
- CountryRepublic of Korea
- Language:English
-
Abstract:
Imatinib, the first-line treatment in patients with advanced gastrointestinal stromal tumors (GIST), is generally well tolerated, although some patients have difficulty tolerating the standard dose of 400 mg/day. Adjusting imatinib dosage by plasma level monitoring may facilitate management of patients who experience intolerable toxicities due to overexposure to the drug. We present two cases of advanced GIST patients in whom we managed imatinib-related toxicities through dose modifications guided by imatinib plasma level monitoring. Imatinib blood level testing may be a promising approach for fine-tuning imatinib dosage for better tolerability and optimal clinical outcomes in patients with advanced GIST.
